Significados de acute migraine en inglés

Diclofenac potassium is a liquid formulation being developed for acute migraine attacks.

The drug is already marketed for acute migraine.

Most frequent primary forms motivating ED observation are acute migraine attacks, particularly status migrainous, and cluster headache.

Several therapies used in the treatment of acute migraine are thought to be associated with medication overuse headache, including opioids and triptans.

The drug, Treximet, was approved by the U.S. Food and Drug Administration in April 2008 to treat acute migraine attacks in adults.

Frova, which is already approved and marketed for acute migraine, had been widely expected to get a green light for the new indication.

CoLucid's lasmiditan, which has already succeeded in one late-stage trial for acute migraine relief, was licensed to the company by Lilly in 2005.

More knowledge about the involvement of NO in the genesis of migraine headache may also provide possible future therapeutic targets for acute migraine therapy.

Further trials are needed to determine the durability and safety of ubrogepant for acute migraine treatment and to compare it with other drugs for migraine.